Article
Early treatment with interferon beta-1a may delay MS onset
Washington, DC-Early treatment of patients at high risk for developing multiple sclerosis (MS), i.e., those with optic neuritis, may be beneficial. The use of interferon beta-1a in these patients at the first sign of optic neuritis or other neurologic symptoms with silent lesions on magnetic resonance imaging (MRI) may significantly delay the development of MS.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
